BL 249
Latest Information Update: 28 Feb 2018
Price :
$50 *
At a glance
- Originator Biolab Sanus Farmaceutica
- Class Nonsteroidal anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for preclinical development in Inflammation in Brazil
- 01 Jan 2014 Preclinical trials in Inflammation in Brazil (unspecified route)